Table 4 summarises these findings. While EGFR overexpression determined by immunohistochemistry is not able to predict response to cetuximab, EGFR amplification was reported to be a good indicator of sensitivity to cetuximab in colorectal cancer. Nuclear factor-kB activation results in an increased resistance to chemotherapy, and the administration of an EGFR inhibitor seems to be able to revert this resistance (Sclabas et al, 2003). Here, EGFR is linked to colorectal cancer.